Navigation Links
NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:4/1/2009

upon achievement of certain development and regulatory milestones, the development and potential benefits of, and the market opportunities for, NovaBay's product candidates, as well as other statements that relate to future events or results, are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to: the risk that NovaBay may incur unexpected charges or need to or determined to engage in research and development not previously planned, which will cause NovaBay's cash burn to be greater than it expects; risks and uncertainties relating to difficulties or delays in discovery, development, testing, production and marketing of the company's product candidates; unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates; the uncertainty of patent protection for the company's intellectual property or trade secrets; the company's ability to obtain additional financing as necessary; results obtained in animal models may not be obtained in humans; and the risk of unexpected delays in the regulatory process which may delay the commencement or completion of clinical trials. Other risks relating to NovaBay and Aganocide(R) compounds, including risks that could cause actual results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Annual Report on Form 10-K for the period ended December 31, 2008, under the caption "Risk Factors" in Item 1A of Part I of that report, filed with the Securities and Exchange Commission on March 31, 2009. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revis
'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
3. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
10. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 The new research ... (High & Medium), Sub-type (Primary & Secondary), and ... & Transportation & Power Generation) - Trends and ... market with analysis and forecasting of the market ... Tables with 52 Figures spread through 146 Pages ...
(Date:10/27/2014)... NEW YORK , Oct. 27, 2014 ... in the recent Ebola concern in the ... for the virus.  The healthcare market researcher said the ... of in vitro diagnostic tests for the detection of ... sensitivity has proved useful.  Kalorama routinely assess the IVD ...
(Date:10/27/2014)... Called the NOAH Protocol, this investigative ... of pediatric brain cancer. The implications for groundbreaking ... years of research and development. Amber Larkin, the ... mom's determination can make a difference. , ... it’s only fitting that we’ve received FDA approval ...
(Date:10/27/2014)... Pa. , Oct. 27, 2014 ... Foundation of America (CCFA) announced today the launch ... , an educational campaign designed to ... diseases (IBD) on the paired role of nutrition ... To view the multimedia assets associated with this ...
Breaking Biology Technology:Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 2Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 3Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign 4
... 2011 Although top bio-pharmaceutical companies agree that Key ... of a new product, increasing competition has made it ... the role of Medical Science Liaisons (MSLs) in forging ... recent years. In fact, today, ...
... YORK, March 21, 2011 Reportlinker.com announces that ... its catalogue: Global Nanobiotechnology Industry ... This report analyzes the worldwide markets for Nanobiotechnology ... - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials ...
... China PharmaHub Corp. (OTC Bulletin Board: CPHB ... that it has signed a exclusive worldwide license agreement ... develop, commercialize and market a universal donor blood product ... Professor of Medicine and Pediatrics Dr. Ewa Carrier. The ...
Cached Biology Technology:Newly Updated for 2011: Medical Science Liaison Study Shows Growth in KOL Outreach, Impact 2Reportlinker Adds Global Nanobiotechnology Industry 2Reportlinker Adds Global Nanobiotechnology Industry 3Reportlinker Adds Global Nanobiotechnology Industry 4Reportlinker Adds Global Nanobiotechnology Industry 5Reportlinker Adds Global Nanobiotechnology Industry 6Reportlinker Adds Global Nanobiotechnology Industry 7Reportlinker Adds Global Nanobiotechnology Industry 8Reportlinker Adds Global Nanobiotechnology Industry 9Reportlinker Adds Global Nanobiotechnology Industry 10Reportlinker Adds Global Nanobiotechnology Industry 11Reportlinker Adds Global Nanobiotechnology Industry 12Reportlinker Adds Global Nanobiotechnology Industry 13Reportlinker Adds Global Nanobiotechnology Industry 14Reportlinker Adds Global Nanobiotechnology Industry 15Reportlinker Adds Global Nanobiotechnology Industry 16Reportlinker Adds Global Nanobiotechnology Industry 17China PharmaHub In-Licenses Universal Donor Red Blood Cells Technology Exclusively From University of California, San Diego 2
(Date:10/29/2014)... As bodies decompose, their types and numbers of ... provide could mean the difference between a closed ... University is using a more than $866,000 U.S. ... investigators examine these changing populations. The microbial communities ... of death, gender, race, socioeconomic relations and more, ...
(Date:10/29/2014)... — Cambridge, MA and Hebei, China — BGI Tech ... quality sequencing of the Jujube genome. Jujube is the ... the Jujube genome is particularly difficult to sequence due ... It is the first time that a genome in ... has been recently published in Nature Communications ...
(Date:10/29/2014)... kidney cancer patients in Europe sheds light on the ... apparent link between exposure to aristolochic acid and incidence ... by an international team led by scientists from the ... underscores the importance of investigating possible sources of exposure ... the Aristolochia genus, also has been suspected of causing ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2BGI Tech and Hebei Agricultural University complete the genome sequencing of the jujube tree 2Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3
... in Clive Svendsen,s lab dishes, he couldn,t have been ... type lost in patients with the devastating neurological disease ... Wisconsin-Madison stem cell biologist had recreated the hallmarks of ... derived from a patient. By allowing scientists the ...
... genes that control the handedness of snail shells, and they ... humans to set up the left and right sides of ... publication in Nature by University of California, Berkeley, ... establishing the left-right asymmetry of animals for 500-650 million years, ...
... Thirteen UC Riverside researchers have been named fellows of ... Including this years fellows, the total number of UCR ... distinction is 172., Election as a fellow is an ... year AAAS gave this honor to 486 of its ...
Cached Biology News:Patient-derived induced stem cells retain disease traits 2Patient-derived induced stem cells retain disease traits 3Snails and humans use same genes to tell right from left 2Snails and humans use same genes to tell right from left 3Snails and humans use same genes to tell right from left 413 UCR faculty members recognized by American Association for the Advancement of Science 213 UCR faculty members recognized by American Association for the Advancement of Science 3
Chlamydia pneumoniae (TWAR)...
Mouse anti-HIV-Imn PND Class: Antibody Product Group: Bacterial and Viral Antigen...
Mouse monoclonal [CP23] to Ricin communis ( Abpromise for all tested applications)....
... Antibody - Red, 20X ... antibody at 20X concentration for use ... assays. Quality Assurance ... FarRed fluorescence polarization assays. ...
Biology Products: